SS Innovations Welcomes “Father of Surgical Robotics” Dr. Fredric Moll to Board
SS Innovations International (OTC: SSII) has announced the addition of Dr. Fredric Moll to its Board of Directors as Vice Chairman. Dr. Moll, known as the 'father of surgical robotics', brings extensive industry experience as the founder of Intuitive Surgical and developer of the da Vinci surgical robotic system. He recently served as Chief Development Officer for Johnson & Johnson Medical Devices Companies and was co-founder and CEO of Auris Health.
SS Innovations recently launched the SSI Mantra 3, an advanced surgical robotic system designed for multi-specialty usage. The company is currently seeking FDA approval, expected in late 2025. Dr. Moll's appointment comes at a time of global growth for SS Innovations, with the company aiming to make robotic surgery more affordable and accessible worldwide.
SS Innovations International (OTC: SSII) ha annunciato l'aggiunta del Dr. Fredric Moll al suo Consiglio di Amministrazione come Vice Presidente. Il Dr. Moll, conosciuto come il 'padre della robotica chirurgica', porta con sé una vasta esperienza nel settore come fondatore di Intuitive Surgical e sviluppatore del sistema robotico chirurgico da Vinci. Recentemente ha ricoperto il ruolo di Chief Development Officer presso le aziende di dispositivi medici Johnson & Johnson ed è stato co-fondatore e CEO di Auris Health.
SS Innovations ha recentemente lanciato il SSI Mantra 3, un avanzato sistema robotico chirurgico progettato per un utilizzo multi-specialistico. L'azienda sta attualmente cercando l'approvazione della FDA, prevista per la fine del 2025. La nomina del Dr. Moll avviene in un periodo di crescita globale per SS Innovations, con l’azienda che mira a rendere la chirurgia robotica più accessibile e conveniente in tutto il mondo.
SS Innovations International (OTC: SSII) ha anunciado la incorporación del Dr. Fredric Moll a su Junta Directiva como Vicepresidente. El Dr. Moll, conocido como el 'padre de la robótica quirúrgica', aporta una amplia experiencia en la industria como fundador de Intuitive Surgical y desarrollador del sistema robótico quirúrgico da Vinci. Recientemente se desempeñó como Director de Desarrollo en las empresas de dispositivos médicos de Johnson & Johnson y fue cofundador y CEO de Auris Health.
SS Innovations lanzó recientemente el SSI Mantra 3, un avanzado sistema robótico quirúrgico diseñado para un uso multi-especialidad. La compañía está buscando actualmente la aprobación de la FDA, que se espera para finales de 2025. La designación del Dr. Moll se produce en un momento de crecimiento global para SS Innovations, que busca hacer que la cirugía robótica sea más asequible y accesible a nivel mundial.
SS Innovations International (OTC: SSII)는 Dr. Fredric Moll을 이사회의 부회장으로 추가한다고 발표했습니다. Dr. Moll은 '수술 로봇의 아버지'로 알려져 있으며, Intuitive Surgical의 창립자이자 다빈치 수술 로봇 시스템의 개발자로서 폭넓은 산업 경험을 제공합니다. 그는 최근 Johnson & Johnson 의료 기기 회사의 최고 개발 책임자로 일했으며 Auris Health의 공동 설립자 겸 CEO였습니다.
SS Innovations는 최근에 다목적 사용을 위해 설계된 첨단 수술 로봇 시스템인 SSI Mantra 3를 출시했습니다. 이 회사는 현재 2025년 말로 예상되는 FDA 승인을 추구하고 있습니다. Moll 박사의 임명은 SS Innovations가 전 세계적으로 로봇 수술을 더 저렴하고 접근 가능하게 만들고자 하는 세계적 성장의 시점에서 이루어졌습니다.
SS Innovations International (OTC: SSII) a annoncé l'ajout du Dr. Fredric Moll à son Conseil d'Administration en tant que Vice-Président. Le Dr. Moll, connu comme le 'père de la robotique chirurgicale', apporte une vaste expérience dans l'industrie en tant que fondateur d'Intuitive Surgical et développeur du système robotique chirurgical da Vinci. Il a récemment été Directeur du Développement pour les entreprises de dispositifs médicaux de Johnson & Johnson et a été co-fondateur et PDG d'Auris Health.
SS Innovations a récemment lancé le SSI Mantra 3, un système robotique chirurgical avancé conçu pour un usage multi-spécialité. La société cherche actuellement l'approbation de la FDA, prévue pour fin 2025. La nomination du Dr. Moll intervient à un moment de croissance mondiale pour SS Innovations, l'entreprise visant à rendre la chirurgie robotique plus abordable et accessible dans le monde entier.
SS Innovations International (OTC: SSII) hat die Ernennung von Dr. Fredric Moll zum stellvertretenden Vorsitzenden des Aufsichtsrats bekannt gegeben. Dr. Moll, bekannt als 'Vater der chirurgischen Robotik', bringt umfangreiche Branchenerfahrung als Gründer von Intuitive Surgical und Entwickler des da Vinci-chirurgischen Robotersystems mit. Zuletzt war er Chief Development Officer der Johnson & Johnson Medical Devices Companies und war Mitbegründer sowie CEO von Auris Health.
SS Innovations hat kürzlich das SSI Mantra 3 auf den Markt gebracht, ein fortschrittliches chirurgisches Robotersystem, das für die Verwendung in mehreren Fachrichtungen entwickelt wurde. Das Unternehmen strebt derzeit die FDA-Zulassung an, die für Ende 2025 erwartet wird. Die Ernennung von Dr. Moll erfolgt in einer Phase des globalen Wachstums für SS Innovations, wobei das Unternehmen die robotergestützte Chirurgie weltweit erschwinglicher und zugänglicher machen möchte.
- Addition of Dr. Fredric Moll, a renowned expert in surgical robotics, to the Board of Directors
- Launch of SSI Mantra 3, an advanced multi-specialty surgical robotic system
- FDA approval process underway with expected approval in late 2025
- Company's focus on making robotic surgery more affordable and accessible globally
- FDA approval for the SSI Mantra 3 system not expected until late 2025, potentially limiting near-term revenue opportunities
Dr. Moll, founder of Intuitive Surgical, to serve as Vice Chairman
FORT LAUDERDALE, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, is pleased to announce the addition of Dr. Fredric Moll to its Board of Directors, where he will serve as Vice Chairman. Dr. Moll is the founder of Intuitive Surgical and is widely regarded as the “father of surgical robotics.”
Dr. Moll brings a wealth of industry experience and expertise to the board: He oversaw the development and commercialization of the da Vinci surgical robotic system. He most recently served as Chief Development Officer for Johnson & Johnson Medical Devices Companies from April 2019 to March 2023. Dr. Moll was a co-founder, Chairman and Chief Executive Officer of Auris Health, Inc., a robotics medical device company that was acquired by Johnson & Johnson in 2019. Dr. Moll is also the Founding Partner of Sonder Capital Management, LLC, a healthcare venture capital investment firm. He served on the board of Shockwave Medical, Inc. from March 2011 through its acquisition by Johnson & Johnson in May 2024. Dr. Moll was an early investor in Avra Medical Robotics and is a current investor in SS Innovations.
“The strength and caliber of Dr. Moll’s leadership is peerless, and he will be a tremendous addition to our Board of Directors,” said Dr. Sudhir Srivastava, SS Innovations Chairman and CEO . “Joining us during the most robust phase of global growth to date, his appointment is perfectly timed. As a pioneer in robotic surgery, Dr. Moll offers a unique perspective and legacy as well as superior insight on the direction and promising future of the industry and SS Innovations.”
Dr. Moll added, “I am excited to help with SS Innovation’s mission to bring the benefits of robotic surgery not just to more people in the United States but also to the rest of the world. This technology should be available to everyone on the planet, and I believe the Company successfully addresses the reasons why others have not yet been able to do so. It is much more affordable than what is out there now without sacrificing any clinical capabilities. It even has capabilities such as in cardiac that no one else even has. I also believe that the system’s proven telesurgery capabilities as well as its related teaching and proctoring tools will prove invaluable.”
Earlier this year, SS Innovations launched the SSI Mantra 3, the newest and most advanced version of its surgical robotic system that makes possible more affordable and accessible surgical care across the globe.
The SSi Mantra 3 provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more while engaging with surgeons and surgical teams to improve safety and efficiency during procedures. The regulatory approval process from the U.S. Food and Drug Administration (FDA) is already underway, and SS Innovations anticipates receiving approval to market in the latter part 2025.
About SS Innovations International, Inc.
SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra” its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at ssinnovations.com or LinkedIn for updates.
About SSi Mantra
Supporting advanced, affordable, and accessible robotic surgery, the SSi Mantra Surgical Robotic System provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more. With its modular arm configuration, 3D 4K vision open-console design and superior ergonomics, the system engages with the surgeon and surgical teams to improve safety and efficiency during procedures. The SSi Mantra system has received Indian Medical Device regulatory approval (CDSCO) and is clinically validated in India in more than 80 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and the European Union and anticipates receiving FDA approval to market and CE Mark approval in 2025.
Forward-Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations International’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Follow us on:
LinkedIn: https://www.linkedin.com/company/ssinnovationsgroup/
YouTube: https://www.youtube.com/@ssinnovations
For media inquiries, please contact:
+1-212-739-0300
FAQ
Who is Dr. Fredric Moll and what role will he play at SS Innovations (SSII)?
What is the SSI Mantra 3 and when is it expected to receive FDA approval?
How does SS Innovations (SSII) aim to make robotic surgery more accessible?
What specialties can the SSI Mantra 3 surgical robot be used for?
